Table 2. Baseline characteristics of 1513 patients with type 2 diabetes and overt nephropathy according to tertile of baseline serum creatinine concentration and randomization to losartan or placebo treatment

Lowest Tertile (Range, 0.9–1.6 mg/dl; Mean ± SD, 1.4 ± 0.1 mg/dl)Middle Tertile (Range, 1.6–2.0 mg/dl; Mean ± SD, 1.8 ± 0.1 mg/dl)Highest Tertile (Range, 2.1–3.6 mg/dl; Mean ± SD, 2.4 ± 0.3 mg/dl)
LosartanPlaceboLosartanPlaceboLosartanPlacebo
Patients (n)239255264244248263
Asian/black/white/hispanic/other (%)12/19/52/16/112/17/48/22/117/15/46/20/221/13/51/14/118/16/45/20/120/11/49/17/2
Clinical parameters
    Age (yr)59.6 ± 7.460.2 ± 7.560.7 ± 7.260.3 ± 7.659.6 ± 7.460.5 ± 7.4
    male gender (%)535865736764
    body mass index (kg/m2)30.9 ± 6.629.8 ± 6.230.0 ± 5.929.3 ± 5.929.0 ± 6.429.2 ± 6.4
    systolic BP (mmHg)149 ± 18149 ± 19152 ± 19153 ± 20154 ± 19157 ± 20
    diastolic BP (mmHg)82 ± 1083 ± 1083 ± 1082 ± 1182 ± 1183 ± 10
    mean BP (mmHg)104 ± 11105 ± 11106 ± 11106 ± 13106 ± 11108 ± 11
    oral antidiabetic drugs/insulin (%/%)55/6255/5848/5953/5542/6442/64
    smoking (%)202020151815
Laboratory parameters
    HbA1C (%)8.7 ± 1.78.7 ± 1.78.6 ± 1.68.4 ± 1.68.3 ± 1.68.2 ± 1.4
    total cholesterol (mg/dl)228 ± 54227 ± 54227 ± 57229 ± 52227 ± 55230 ± 60
    HDL cholesterol (mg/dl)47 ± 1747 ± 1445 ± 1544 ± 1543 ± 1444 ± 14
    triglycerides (mg/dl)239 ± 195222 ± 208207 ± 174241 ± 235194 ± 168213 ± 150
    potassium (mEq/L)4.5 ± 0.54.6 ± 0.54.6 ± 0.44.6 ± 0.54.7 ± 0.54.7 ± 0.5
    uric acid (mg/dl)6.2 ± 1.66.1 ± 1.56.8 ± 1.76.9 ± 1.67.0 ± 1.77.1 ± 1.7
    creatinine clearance (ml/min per 1.73 m2)
    mean ± SD50.7 ± 6.050.8 ± 5.739.1 ± 2.739.1 ± 2.828.9 ± 3.428.8 ± 3.3
    range43.1–76.744.5–76.734.5–43.134.5–43.119.2–33.721.6–33.7
    median albumin/creatinine ratio (g/mg)9478821045117817371800